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Polyphenols act synergistically with doxorubicin and etoposide
in leukaemia cell lines
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The study aimed to assess the effects of polyphenols when used in combination with doxorubicin and etoposide, and to determine
whether polyphenols sensitised leukaemia cells, causing inhibition of cell proliferation, cell cycle arrest and induction of apoptosis.
This study is based on ﬁndings in solid cancer tumours, which have shown that polyphenols can sensitize cells to chemotherapy,
and induce apoptosis and/or cell-cycle arrest. This could enable a reduction of chemotherapy dose and off-target effects, whilst
maintaining treatment efﬁcacy. Quercetin, apigenin, emodin, rhein and cis-stilbene were investigated alone and in combination
with etoposide and doxorubicin in two lymphoid and two myeloid leukaemia cells lines. Measurements were made of ATP levels
(using CellTiter-Glo assay) as an indication of total cell number, cell cycle progression (using propidium iodide staining and ﬂow
cytometry) and apoptosis (NucView caspase 3 assay and Hoechst 33342/propidium iodide staining). Effects of combination
treatments on caspases 3, 8 and 9 activity were determined using Glo luminescent assays, glutathione levels were measured using
the GSH-Glo Glutathione Assay and DNA damage determined by anti-γH2AX staining. Doxorubicin and etoposide in combination
with polyphenols synergistically reduced ATP levels, induced apoptosis and increased S and/or G2/M phase cell cycle arrest in
lymphoid leukaemia cell lines. However, in the myeloid cell lines the effects of the combination treatments varied; doxorubicin had
a synergistic or additive effect when combined with quercetin, apigenin, emodin, and cis-stilbene, but had an antagonistic effect
when combined with rhein. Combination treatment caused a synergistic downregulation of glutathione levels and increased DNA
damage, driving apoptosis via caspase 8 and 9 activation. However, in myeloid cells where antagonistic effects were observed, this
was associated with increased glutathione levels and a reduction in DNA damage and apoptosis. This study has demonstrated that
doxorubicin and etoposide activity were enhanced by polyphenols in lymphoid leukaemia cells, however, differential responses
were seen in myeloid cells with antagonistic responses seen in some combination therapies.
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INTRODUCTION
Despite considerable improvements in tolerance and efﬁcacy of
chemotherapeutic agents, the mortality of leukaemia is still high.1
Topoisomerase II inhibitors such as doxorubicin and etoposide are the
most common chemotherapeutic agents used for leukaemia
treatment.1,2 Unfortunately, these agents are commonly associated
with severe side effects; and drug resistance is common.1–6 As such
combination treatments are under investigation as they could
enhance the efﬁcacy of standard chemotherapy agents, and decrease
development of drug resistance, toxicity and side effects.1–3,5,7
One strategy could be combination of chemotherapy agents with
bioactive compounds such as polyphenols. We have previously
shown that a number of polyphenols reduced cell ATP levels, caused
cell cycle arrest and induce apoptosis, particularly in lymphoid
leukaemia cells lines, whilst having limited effects on normal
haematopoietic cells.8 Within our previous study, eight polyphenols
selected as representatives of the major polyphenol classes were
investigated, and the most potent polyphenols identiﬁed were
quercetin, apigenin, emodin, rhein and cis-stilbene.8
In a number of solid tumours, polyphenols have been shown to
work synergistically with cisplatin and doxorubicin and induce
apoptosis.3,9,10 Thus, it may be possible for the polyphenols to
enhance action of the standard chemotherapy treatments,
however, no studies have investigated the combination effects
of polyphenols with topoisomerase II inhibitors in leukaemia cells.
This study investigated whether the polyphenols identiﬁed
previously8 have a synergistic effect when combined with
topoisomerase II inhibitor agents (doxorubicin and etoposide)
on cell ATP levels, apoptosis and cell cycle progression within the
lymphoid and myeloid leukaemia cell lines. The mechanism of
action of these combination treatments was also investigated.
RESULTS
Effects of topoisomerase inhibitors alone on ATP levels and
caspase 3 activity in leukaemia cell lines
Doxorubicin and etoposide induced a dose-dependant decrease
in ATP levels and increase in caspase 3 activity in all cell lines
although effects on non-tumour control cells were reduced
compared with leukaemia cells (Figure 1). The lowest-signiﬁcant
dose (LSD) for doxorubicin and etoposide alone (μM), which
reduced ATP levels compared with the vehicle control at 24 h, was
dependant on all cell types. The LSD for ATP activity for both
doxorubicin and etoposide were: 0.01 μM in Jurkat; 0.01 μM in
CCRF-CEM; 0.01 μM in THP-1; 0.4 μM in KG-1a; 0.4 μM in CD34+
HSCs and 0.4 μM in CD133+ HSCs (Figures 1a and b). Similar LSDs
were observed for induction of caspase 3 activity although this
varied slightly dependant on chemotherapy agent and cell line
investigated. For doxorubicin, the LSD for caspase 3 activity were:
0.01 μM in Jurkat; 0.01 μM in CCRF-CEM; 0.4 μM in THP-1; 0.4 μM in
KG-1a; 0.4 μM in CD34+ HSCs and 0.4 μM in CD133+ HSCs
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(Figure 1c). For etoposide, the LSD for caspase 3 activity were:
0.01 μM in Jurkat; 0.01 μM in CCRF-CEM; 0.01 μM in THP-1; 0.4 μM
in KG-1a; 0.4 μM in CD34+ HSCs and 0.4 μM in CD133+ HSCs
(Figure 1d).
Effect of Topoisomerase inhibitors in combination with
polyphenols on ATP levels in leukaemia cell lines and non-tumour
cells
Doxorubicin and etoposide when used in combination with
quercetin caused a synergistic reduction of ATP levels (Po0.05) in
both lymphoid and myeloid cell lines, however, minimal changes
were found in non-tumour control cells (Figure 2). Doxorubicin
combined with apigenin induced a synergistic reduction in ATP
levels in three out of four leukaemia cell lines (CCRF-CEM, Jurkat and
THP-1) and had an additive effect in KG-1a cells (Po0.05) (Figure 2).
Etoposide when combined with apigenin induced a synergistic
decrease in ATP levels in THP-1 myeloid cell line only, but had
additive effects in all other leukaemia cell lines. Limited effects were
seen in non-tumour control cells (Po0.05) (Figure 2).
A synergistic reduction in ATP levels in the lymphoid leukaemia
cell lines was also seen when doxorubicin or etoposide was
combined with emodin, rhein or cis-stilbene (Po0.05) (Figure 2).
However, in the myeloid cell lines, when doxorubicin or etoposide
was combined with emodin, rhein or cis-stilbene, no synergistic
effects were seen and responses varied between additive,
competitively antagonistic or antagonistic (Figure 2). In the non-
tumour control cells both rhein and cis-stilbene antagonised the
effects of both doxorubicin and etoposide (Figure 2).
Combination therapy effects on caspase 3 activity
Doxorubicin and etoposide when used in combination with
quercetin produced a synergistic increase in caspase 3 activity
in all leukaemia cell lines (Po0.05) (Figure 3). Similarly,
doxorubicin when used in combination with apigenin synergisti-
cally increased caspase 3 activity in three out of four of the
leukaemia cell lines (CCRF-CEM, Jurkat and THP-1) (Po0.05),
however, this combination only had an additive effect in KG-1a
cells (Po0.05). A synergistic effect was observed when etoposide
and apigenin were combined in the treatment of
THP-1 cells and an additive effect was observed in the three
remaining leukaemia cells lines (CCRF-CEM, Jurkat and KG-1a)
(Po0.05) (Figure 3). Both doxorubicin and etoposide when used
in combination with emodin, rhein or cis-stilbene synergistically
increased caspase 3 activity in the lymphoid cell lines only
(Po0.05) (Figure 3). In the myeloid cell lines, doxorubicin and
etoposide when combined with emodin and cis-stilbene differ-
ently modulated caspase 3 activity, having either an additive,
competitive-antagonistic or antagonistic effect (Po0.05)
(Figure 3). In contrast, both doxorubicin and etoposide when
combined with rhein produced either a competitive-antagonistic
or antagonistic effect on apoptosis (Po0.05) (Figure 3). In the
non-tumour control cells (CD34+ HSC and CD133+ HSC), both
doxorubicin and etoposide when combined with each of the
polyphenols had a minimal effect on caspase 3 activity
(Figure 3). These results were further conﬁrmed with morpho-
logical assessment of apoptosis, and were found to follow the
same trends shown by the caspase 3 data (data not shown).
Combination effect on caspases 8 and 9 activity
Doxorubicin and etoposide when used in combination with each
polyphenol caused a synergistic increase in caspase 9 activity
(Po0.05) in all leukaemia cell lines (Figure 4). In contrast a
synergistic effect on caspase 8 was only seen in CCRF-CEM cells
when doxorubicin was combined with quercetin (Po0.05) or
when etoposide was combined with emodin, rhein or cis-stilbene
(Po0.05) (Figure 4). In all other combination treatments, in all
other cell lines there was an additive increase in caspase 8 activity
Figure 1. Effect of doxorubicin and etoposide on (a and b) ATP levels and (c and d) caspase 3 activity in two lymphoid leukaemia (CCRF-CEM
and Jurkat), two myeloid leukaemia (THP-1 and KG-1a) cell lines and two non-tumour control cells (CD133+ HSC and CD34+ HSC). The lowest-
signiﬁcant doses (LSD) which signiﬁcantly reduced ATP levels and induced apoptosis was determined for each etoposide inhibitor in each cell
lines. The '*' indicated LSD in each cell line.
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only (Figure 4); the only exception was in the CCRF-CEM cells
when treated with doxorubicin and emodin or rhein which
showed no caspase 8 activity.
Combination effects on cell cycle progression
Within lymphoid leukaemia cell lines when doxorubicin or
etoposide were combined with each of the polyphenol, interactive
Figure 2. The effect of doxorubicin (DOX) and etoposide (ETP) when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO),
rhein (RH) or cis-stilbene (CIS) on ATP levels in two lymphoid leukaemia cell lines (Jurkat and CCRF-CEM), two myeloid leukaemia cell lines
(THP-1 and KG-1a) and two non-tumour control cells (CD133+ HSC and CD34+ HSC). This was evaluated by CellTiter-Glo assay. Cells were
treated with doxorubicin or etoposide and polyphenols alone and in combination for 24 h using their lowest-signiﬁcant doses (LSD); together
with a vehicle control. All data were normalised to the vehicle control, which was assigned 100% cell viability. The data were expressed as
medians and ranges (n= 4). The black bars show the vehicle controls and treatments alone; the coloured bars indicate signiﬁcant additive
effects in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink. Statistical signiﬁcance
was set at P⩽ 0.05 compared with vehicle control, drugs alone and expected values of individual drugs when combined.
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Figure 3. The effect of doxorubicin (DOX) and etoposide (ETP) when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO),
rhein (RH) or cis-stilbene (CIS) on caspase 3 activity of two lymphoid leukaemia cell lines (Jurkat and CCRF-CEM), two myeloid leukaemia cell
lines (THP-1 and KG-1a) and two non-tumour control cells (CD133+ HSC and CD34+ HSC). This was evaluated by NucView caspase 3 activity
assay. Cells were treated with doxorubicin or etoposide and polyphenols alone and in combination for 24 h using their lowest-signiﬁcant
doses (LSD), together with a vehicle control. All data were normalised to the vehicle control, which was assigned a 0% apoptotic level. The
data were expressed as medians with ranges (n= 4). The black bars show the vehicle controls and treatments alone; the coloured bars indicate
signiﬁcant additive effects in brown, synergistic effects in yellow, competitive antagonistic effects in purple and antagonistic effects in pink.
Statistical signiﬁcance was set at P⩽ 0.05 compared with vehicle control, drugs alone and expected values of individual drugs effects.
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Figure 4. The effect of doxorubicin (DOX) and etoposide (ETP) on caspases 8 and 9 activity when used in combination with quercetin (QUE),
apigenin (AP), emodin (EMO), rhein (RH) or cis-stilbene (CIS) in lymphoid leukaemia cell lines (Jurkat and CCRF-CEM); and when used in
combination with QUE or AP in myeloid leukaemia cell lines (THP-1 and KG-1a). This was evaluated by Caspases-Glo Luminescent 8 and 9
Assays. Cells were treated with DOX or ETP and polyphenols alone and in combination for 24 h using their lowest-signiﬁcant doses (LSD). Data
were normalised to the vehicle control, which was assigned a 0 RLU. The data were expressed as medians with ranges (n= 4). The black bars
show the vehicle controls and treatments alone; the coloured bars indicate signiﬁcant additive effects in brown, synergistic effects in yellow,
competitive antagonistic effects in purple and antagonistic effects in pink. Statistical signiﬁcance was set at P⩽ 0.05 compared with vehicle
control, drugs alone and expected values of individual drugs effects.
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effects were observed with cells accumulating in the S and/or
G2/M phase of the cell cycle (Po0.05) (Table 1). In myeloid cell
lines, an interactive effect was observed when both doxorubicin
and etoposide were combined with quercetin or apigenin in the
THP-1 cells (Po0.05), and in KG1a cells, when etoposide was
combined with apigenin: inducing an S and G2/M cell cycle arrest
(Po0.05) (Table 1). In the THP-1 cells, when doxorubicin was in
combination with cis-stilbene an interactive effect was seen with S
phase arrest (Po0.05) (Table 1). In contrast, in the myeloid cell
lines an antagonistic effect with no cell cycle arrest was seen when
doxorubicin was combined with emodin or rhein, and when
etoposide was combined with rhein and cis-stilbene (Po0.05)
(Table 1). All other combination treatments in the myeloid cell
lines showed no interactions between the polyphenols and
topoisomerase inhibitors although cells accumulated in S and G2
phase of the cell cycle (Table 1).
Glutathione levels and effects of combination treatments
Basal glutathione levels varied between cells and these followed
the following pattern: CCRF-CEMoJurkatoCD34+ HSCoTHP-1
oKG-1aoCD133+ HSC (Figure 5a). Lymphoid leukaemia cell lines
showed signiﬁcantly lower glutathione levels compared with
myeloid leukaemia cell lines and non-tumour control cells
(P⩽ 0.05) (Figure 5a).
Following stimulation with doxorubicin and etoposide in
combination with quercetin or apigenin there was a synergistic
or additive decrease in glutathione levels in all lymphoid and
myeloid cell lines (Po0.05) (Figure 5b). Similarly when doxor-
ubicin and etoposide were used in combination with emodin,
rhein and cis-stilbene this too caused a synergistic reduction in
glutathione levels, but only in lymphoid leukaemia cell lines
(Po0.05) (Figure 5b). In contrast in myeloid cell lines, when
doxorubicin was combined with emodin and rhein, and etoposide
was combined with rhein and cis-stilbene there was a competitive
antagonistic or antagonist effect, and glutathione levels were
increased (Po0.05) (Figure 5b). However, when etoposide was
combined with emodin or cis-stilbene in myeloid cell lines there
was an additive decrease in glutathione levels (Po0.05)
(Figure 5b). These results were further conﬁrmed using CMFDA
staining, and were found to follow the same trends shown by the
GSH-Glo Glutathione Assay (Promega, Southampton, UK; data not
shown).
Effects of combination of polyphenols and topoisomerase
inhibitors on γH2AX foci formation
Doxorubicin and etoposide when used in combination with
quercetin or apigenin caused a synergistic increase in γH2AX foci
(Po0.05) in all lymphoid and myeloid cell lines (Po0.05)
(Figure 6). However, when doxorubicin and etoposide were
combined with emodin, rhein or cis-stilbene there was a
synergistic increase in γH2AX foci formation only in the lymphoid
leukaemia cell lines (Po0.05) (Figure 6).
DISCUSSION
This study investigated the combination effects of two topoi-
somerase II inhibitors (doxorubicin and etoposide) and ﬁve
polyphenols (quercetin, apigenin, emodin, rhein and cis-stilbene).
These polyphenols have been shown to induce apoptosis and
arrest cell cycle in leukaemia cell lines.8 Here, we demonstrated
combination effects on ATP levels, induction of apoptosis and cell
cycle arrest in leukaemia cell lines. Topoisomerase II inhibitor
agents were synergistically enhanced by polyphenols in the
lymphoid leukaemia cell lines, while their effects were differen-
tially modulated by polyphenols in the myeloid leukaemia cell
lines. These differential combination effects depended on cell
lineage and/or polyphenol used. In the non-tumour control cells
(CD34+HSC and CD133+HSC), all polyphenols were shown to
reduce the toxicity of topoisomerase II inhibitors on ATP levels and
caspase 3 activity, suggesting polyphenols could be protective in
normal cells, and hence could reduce off-target effects.
Interestingly when doxorubicin and etoposide were used in
combination with each polyphenol in lymphoid leukaemia cells
they synergistically reduced ATP levels, induced apoptosis and
increased cell cycle arrest, while in myeloid cell lines synergistic
effects were only seen following combination treatments with
quercetin and apigenin.
Quercetin has been shown in a number of solid tumours to
enhance the activity of doxorubicin.9–13 Doxorubicin in combina-
tion with quercetin is highly effective against a number of tumour
types including lymphoid and myeloid leukaemias. Doxorubicin
and quercetin combination treatment in murine breast cancer
cells caused synergistic inhibition of cell proliferation and
metastasis to the lung, via increased IFN-γ and IL-2 levels and
induction of immunogenic cancer cell death (apoptosis of CD4+ or
CD8+ T cells).11 Similarly, in human breast cancer cell lines (MCF-7,
Table 1. The effect of doxorubicin (DOX) and etoposide (ETP) on cell cycle progression, when used in combination with quercetin, apigenin, emodin,
rhein, or cis-stilbene in two lymphoid leukaemia cell lines (Jurkat and CCRF-CEM) and two myeloid leukaemia cell lines (THP-1 and KG-1a)
Lymphoid leukaemia Myeloid leukaemia
Jurkat CCRF-CEM THP-1 KG1a
DOX ETP DOX ETP DOX ETP DOX ETP
Quercetin SYN interactive
G2/M
SYN interactive
G2/M
SYN interactive S SYN interactive S
& G2/M
SYN interactive S
& G2/M
SYN interactive S
& G2/M
Non-interactive S
& G2/M
Non-interactive
S & G2/M
Apigenin SYN interactive
G2/M
SYN interactive S SYN interactive S
& G2/M
SYN interactive S
& G2/M
SYN interactive S
& G2/M
SYN interactive S
& G2/M
Non-interactive S
& G2/M
SYN interactive
S & G2/M
Emodin SYN interactive
G2/M
SYN interactive S
& G2/M
SYN interactive S SYN interactive S ANTG no arrest Non-interactive S
& G2/M
ANTG no arrest Non-interactive
S & G2/M
Rhein SYN interactive
G2/M
SYN interactive
G2/M
SYN interactive S SYN interactive
G2/M
ANTG no arrest ANTG no arrest ANTG no arrest ANTG no arrest
Cis-Stilbene SYN interactive
G2/M
SYN interactive
G2/M
SYN interactive S SYN interactive S SYN interactive S ANTG no arrest Non-interactive S
& G2/M
ANTG no arrest
Cell cycle progression was analysed by ﬂow cytometry following propidium iodide staining. Cells were treated with DOX or ETP and polyphenols alone and in
combination for 24 h using their lowest-signiﬁcant doses (LSD) as determined by CellTiter-Glo assay, together with a vehicle control. The percentage of cells in
each phase was analysed with FlowJo software using the Watson (Pragmatic) model. The data were expressed as medians with ranges (n= 4). Statistical
signiﬁcance of combination treatments was determined and compared with the vehicle control and the individual treatments alone. Statistical signiﬁcance
was set at Pr0.05. The combination effects of drugs were statistically shown to be either interactive or non-interactive, and shown to have a synergistic (SYN)
or antagonistic effect (ANTG).
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Figure 5. (a) Basal glutathione (GSH) levels in two lymphoid leukaemia (CCRF-CEM and JURKAT), two myeloid leukaemia (THP-1 and KG-1a) cell
lines; and two non-tumour control (CD133+HSC and CD34+ HSC) cell lines. Untreated cells were evaluated by the GSH-Glo Glutathione Assay. The
data are expressed as median with range in triplicate. Statistical signiﬁcance was set at P⩽0.05. (b) The effect of doxorubicin (DOX) and
etoposide (ETP) when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO), rhein, (RH) or cis-stilbene (CIS) was determined on
GSH levels in two lymphoid leukaemia cell lines (Jurkat and CCRF-CEM) and two myeloid leukaemia cell lines (THP-1 and KG-1a). GSH levels were
evaluated by the GSH-Glo Glutathione Assay. Cells were treated with DOX or ETP and polyphenols alone and in combination for 24 h using their
lowest-signiﬁcant doses (LSD). Data were normalised to the vehicle control, which was assigned 100% of GSH level. The data were expressed as
medians and ranges (n= 4). The black bars show the vehicle controls and treatments alone; the coloured bars indicate a signiﬁcant additive
effect in brown, a synergistic effect in yellow, a competitive antagonistic effect in purple and an antagonistic effect in pink. Statistical signiﬁcance
was set at P⩽0.05 compared with vehicle control, drugs alone and expected values of individual drugs effects.
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MDA-MB-231 and MCF-10A) combination of doxorubicin and
quercetin inhibited cell proliferation and induced apoptosis
through decreased cellular thiol levels and blocked the PKCδ
signalling pathway.10 The treatment of MCF-7 cells with doxor-
ubicin and quercetin caused inhibition of cell proliferation and
invasion via the suppression of hypoxia-inducible factor-1α
and P-glycoprotein.12 Likewise, in human hepatoma cell lines
(SMMC7721 and QGY7701) doxorubicin and quercetin combination
treatment induced apoptosis via accumulation of p53, followed by
the activation of mitochondrial apoptotic pathway, resulting in
activation of caspase 9 and caspase 3.13 Furthermore, it has also
been demonstrated that quercetin reduces the hepatotoxicity
of doxorubicin in normal liver cells both in vitro and in vivo.13
Work by Brantley et al.13 showed that doxorubicin synergistically
interacted with apigenin in human breast cancer cell lines (MDA-
MB-468 and MDA-MB-157) inhibiting cell proliferation and
inducing apoptosis by altering the expression of apoptosis and
proliferation markers such as BAX, Bcl-2, ERK, PARP and survivin.14
There is only one study which has previously investigated the
effect polyphenols have on etoposide treatment; here quercetin
acted synergistically with etoposide and inhibited cell proliferation
and induced apoptosis in colorectal (HCT116) and prostate cancer
(PPC1) cell lines, via upregulation of p53, p21 and BAX, and the
reduction of cyclin B1 and survivin, which led to arrest of the cell
cycle at S and G2/M phases.
15 All these earlier studies are
consistent with our ﬁndings, and suggest that the action of
doxorubicin and etoposide are enhanced by both quercetin and
apigenin.
In the current study, we further demonstrated synergistic
responses were accompanied by a downregulation of glutathione
levels and increased γH2AX foci indicating DNA damage, driving
apoptosis by a synergistic activation of caspase 9 and additive
activation of caspase 8. These results suggest that synergistic
effects are dependent on activation of caspase 9 in particular,
suggesting a major role of intrinsic apoptosis and DNA damage
response; however, as these cells are p53 null16–18 this could not
be a direct regulation through the p53 pathway. Wang et al.,12
demonstrated that doxorubicin when combined with quercetin
causes a synergistic induction of apoptosis through the accumula-
tion of p53, and the activation of the intrinsic apoptotic pathway
Figure 6. The effect of doxorubicin (DOX) and etoposide (ETP) when used in combination with quercetin (QUE), apigenin (AP), emodin (EMO),
rhein, (RH) or cis-stilbene (CIS) on γ-H2AX foci formation (DNA damage marker) of two lymphoid leukaemia cell lines (Jurkat and CCRF-CEM)
and two myeloid leukaemia cell lines (THP-1 and KG-1a). This was evaluated by the immunoﬂuorescent staining using Alexa Fluor 647 Mouse
anti-H2AX (pS139). Cells were treated with DOX or ETP and polyphenols alone and in combination for 24 h using their lowest-signiﬁcant doses
(LSD). The data were expressed as medians and ranges (n= 4). The black bars show the vehicle controls and treatments alone; the coloured
bars indicate a signiﬁcant additive increase in DNA damage in brown, a synergistic increase in DNA damage in yellow, a competitive
antagonistic decrease in DNA damage in purple and an antagonistic decrease in DNA damage in pink. Statistical signiﬁcance was set at
P⩽ 0.05 compared with vehicle control, drugs alone and expected values of individual drugs effects.
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via the activation of caspase 9 and 3 in human hepatoma cell lines
(SMMC7721 and QGY7701).13 Thus it is interesting that the
intrinsic pathway is still activated even within the p53 null cell
lines investigated in the current study.
Here we demonstrated that doxorubicin and etoposide
combined with emodin, rhein or cis-stilbene in myeloid leukaemia
cell lines had differential effects, with some being antagonistic.
Doxorubicin when combined with emodin or rhein, and when
etoposide was combined with rhein or cis-stilbene they induced
antagonistic and/or competitive-antagonistic effects on ATP levels
and apoptosis in the myeloid cell lines. These antagonistic
combination treatments were usually associated with an elevation
in glutathione levels and an absence of elevated DNA damage and
cell cycle arrest.
Few studies have addressed polyphenol-induced antagonism of
anti-tumour agents. Apigenin, galangin and chrysin have been
shown to inhibit the action of cisplatin and doxorubicin,
producing an antagonistic effect on cytotoxicity and induction
of apoptosis in murine leukaemia (L1210) cells.19 It was suggested
that this antagonistic effect was related to the antioxidant activity
of the polyphenols, which could protect against reactive oxygen
species (ROS) that were generated by doxorubicin. Similarly, rutin
hydrate, quercetin dehydrate, hydrocaffeic acid, gallic acid and
tannic acid antagonised bortezomib-induced apoptosis in multiple
myeloma cell lines.20 Previous work has also shown that
polyphenols can serve as either antioxidants or pro-oxidants
depending on cellular conditions, requirement and doses; thus
they can help in the modulation of antioxidant redox system such
as glutathione.21–23 In addition, it has been reported that the
antioxidant activity of polyphenols has a crucial role in their
chemopreventive effect; while their pro-oxidant action may be
important for their anti-cancerous effects.21–23 Here, for the ﬁrst
time we have shown the exact mechanisms of synergism and
antagonism of topoisomerase inhibitors. The action of doxorubicin
and etoposide, when combined with quercetin, apigenin, emodin,
rhein or cis-stilbene was strongly dependent on the modulation of
glutathione levels, caspase cascades and DNA damage within the
leukaemia cell lines. These ﬁndings are supported by Staedler
et al.9 who showed that doxorubicin when combined with
quercetin in human breast cancer cell lines (MCF-7, MDA-
MB-231 and MCF-10A) synergistically inhibited cell proliferation
and induced apoptosis through the reduction of glutathione and
glutathione S-transferase.11
Here, we have shown that the basal glutathione levels of the
leukaemia cell lines strongly correlated with their sensitivity to
both topoisomerase inhibitors and polyphenol treatments. It was
found that the lymphoid leukaemia cell lines had the lowest basal
glutathione levels and were more sensitive to polyphenols and
topoisomerase inhibitor treatments when used alone or in
combination. In contrast, the myeloid leukaemia cell lines had
higher basal glutathione levels compared with non-tumour
control cells and lymphoid cell lines. KG-1a myeloid cell line
displayed the highest glutathione level and hence the greatest
resistance to treatment with topoisomerase inhibitors and
polyphenols.
Indeed, studies have reported that many cancers, including
lung, ovarian, breast, colon, larynx and haematological malig-
nancies have high levels of glutathione.22 This high glutathione
level increases the antioxidant capacity of the cancerous cell
preventing oxidative stress, DNA damage and inhibiting apopto-
sis; as a result this can lead to resistance to cancer treatments.22
This is also commonly associated with increased risk of disease
relapse and resistance to the chemotherapeutics.23,24 In contrast,
some cancers such as melanoma have low glutathione levels,
which decrease the cellular antioxidant capacity and increased
oxidative stress via excessive production of ROS, which can result
in DNA damage and cell death; this increases the sensitivity of
these cancers to treatment.22
The data reported in this study provides new and interesting
information on the role of intracellular glutathione in the
sensitization of leukaemia cells line to polyphenols and topoi-
somerase inhibitor treatment, whether used alone or in combina-
tion. Polyphenols/chemotherapy agents are more effective in cells
with low glutathione content such as lymphoid cells, while less
effective in cells with high glutathione content such myeloid cells.
Cancer cell glutathione activity may predict responses to
chemotherapy polyphenols combination treatments.
Currently, all the present studies reported that glutathione
depletion in cells is strongly correlated to restored apoptosis
induction, and this action could be very useful to increase the
therapeutic efﬁcacy of cancer treatment.22,23,25 It is reported that
glutathione depletion is regulated by both extrinsic and intrinsic
apoptotic signalling cascades at distinct checkpoints.25 In
particularly, glutathione depletion can predispose cells to
apoptosis or directly trigger cell death by modulation of both
the permeability transition pore formation and the activation of
execution caspases.25 It has also been reported that a reduction in
the glutathione content is necessary for the formation of the
apoptosome and activates the intrinsic apoptotic pathway by
oxidation-dependent dimerisation.25 Glutathione depletion has
also been shown to trigger cytochrome c release from the
mitochondria, which can be oxidised for its pro-apoptotic action,
which would need cytosolic glutathione levels to be depleted.25
The antioxidant property of glutathione is strongly linked to the
overexpression of anti-apoptotic Bcl-2, which inhibits
mitochondrial-induced apoptosis.25 Thus to increase the efﬁcacy
of chemotherapy or any cancer treatments, and limit multi-drug
resistance (MDR), it is necessary to decrease glutathione levels in
cancer cells.22,26–28
In those treatment combinations that induced synergistic
accumulation in S and/or G2/M phases of the cell cycle, this was
associated with γH2AX foci formation and DNA damage. Alter-
natively in those combinations in which there were antagonistic
effects there was no arrest of cell cycle and a lack of γH2AX foci
and DNA damage. Mechanistically, γH2AX is phosphorylated by
phosphatidylinositol-3 kinase (PI3K)-like kinases, including ATM,
ATM-Rad3-related kinase (ATR), ATM-related kinase (ATX) and
other cell cycle checkpoint factors such as Chk1 and Chk2.29 Thus
the presence of γH2AX foci is an excellent marker of DNA damage
caused by cytotoxic agents or cancer treatments.29–31 Rajendran
et al.,29 suggested that combination treatments could be very
effective and produced synergistic actions when used to target
DNA damage and interfere with DNA repair in cancer cells. In this
regard, our synergistic combination agents that targeted the DNA
and cause damage and result in cell cycle arrest and/or apoptosis
could be very effective treatments for leukaemia.
In conclusion, doxorubicin and etoposide activity can be
enhanced by polyphenols, particularly in lymphoid leukaemia
cells, although effects were strongly dependent on cell type, with
some interactions being antagonistic in myeloid cell lines. These
actions were strongly dependent on the modulation of glu-
tathione levels and association with the DNA damage in
leukaemia cell lines. Furthermore this study suggests that
combination of doxorubicin and etoposide topoisomerase inhibi-
tors with speciﬁc polyphenols could be promising for the
treatment of lymphoid leukaemias. However, care is required to
avoid potential inhibition of therapies.
MATERIALS AND METHODS
Leukaemia cell lines
Four human leukaemia cell lines were used for this study: two lymphoid
leukaemia cell lines (Jurkat (peripheral blood T cell leukaemia; ATCC:
TIB-152, Middlesex, UK) and CCRF-CEM (acute lymphoblastic leukaemia;
ATCC: CCL-119); which were previously shown to have high sensitivity to
polyphenols;8 together with two myeloid leukaemia cell lines-THP-1 (acute
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monocytic leukaemia; ATCC: TIB-202) and KG-1a (acute myelogenous
leukaemia; ATCC:CCL-243)-which had previously shown resistance to
polyphenols.8 Non-tumour control cells from cord blood (CD34+HSC and
CD133+HSC; Stem cell Technologies, Grenoble, France) were also included
in the study. All cells were tested for mycoplasma contamination using the
MycoAlert TM mycoplasma detection kit (Lonza, MD, USA) and were all
negative throughout the study.
Culture conditions
Cells were maintained in RPMI 1640 (Invitrogen, Paisley, UK) supplemented
with 10% (v/v) foetal bovine serum, 1.5 mM L-Glutamine and 100 μg/ml
penicillin/streptomycin at 37 °C with 5% CO2.
Treatment regimes
Quercetin (Enzo Life Sciences, Exeter, UK), apigenin, emodin, rhein and
cis-stilbene (Sigma, Poole, UK) were prepared as described previously.8
Cells were treated with each polyphenol alone or in combination with the
topoisomerase inhibitors (doxorubicin and etoposide; Sigma). Doxorubicin
was dissolved in sterile distilled H2O, while etoposide was dissolved in
1 : 1 v/v sterile distilled H2O/ethanol. A stock solution of 25mM was
prepared with 10% (v/v) ethanol (Sigma) in serum-free media (Invitrogen)
to generate treatment concentrations between 0.005 and 50 μM.
Dose–response curves were generated for each polyphenol and each
chemotherapy agent. These were used to determine the lowest-signiﬁcant
dose, which signiﬁcantly reduced ATP levels and signiﬁcantly induced
caspase 3 activity when compared with the vehicle control at 24 h. These
LSD doses were used for subsequent polyphenol/chemotherapy combina-
tion work. Signiﬁcance was determined using a Kruskal–Wallis with a
Conover–Inman post hoc test. The LSD for the selected polyphenols was
determined from our previous study.8
The LSDs determined from effects on ATP levels were used in
combination studies investigating effects on ATP levels, cell cycle
progression, DNA damage and glutathione levels, while the LSDs
determined from induction of apoptosis were used in combination studies
investigating effects on induction of apoptosis, caspase 3, 8 and 9
activities.
Two lymphoid leukaemia cell lines (Jurkat and CCRF-CEM) and two
myeloid leukaemia cell lines (THP-1 and KG-1a) and two non-tumour
control cells (CD34+HSC and CD133+HSC) were treated with each
polyphenol and each topoisomerase inhibitor (doxorubicin and etoposide)
alone or in combination at their LSDs, along with a vehicle control, for 24 h.
All treatments were performed in triplicate in three independent
experiments. Following treatments, measurements were made of ATP
levels, cell cycle progression, DNA damage (measured as γH2AX foci),
glutathione levels, induction of apoptosis and caspase 3, 8 and 9 activity.
CellTiter-Glo luminescent cell viability assay
Cells were seeded into white 96-well plates (Fisher Scientiﬁc, Loughbor-
ough, UK) at 2.5 × 103 cells per well and treated with polyphenols and
topoisomerase inhibitors alone and in combination for 24 h, together with
a 0.1% (v/v) ethanol vehicle controls. Following treatments, the CellTiter-
Glo luminescent cell viability assay (Promega) was used to measure ATP
levels, as per manufacturer's instructions.
Apoptosis analysis
NucView caspase 3 activity assay by ﬂow cytometry. Cells were seeded in
12-well plates at 0.5 × 106 cells per well and treated with polyphenols and
topoisomerase inhibitors alone or in combination for 24 h, together with a
0.1% (v/v) ethanol vehicle control. Following treatments, the NucView
caspase 3 activity assay (Cambridge Bioscience, Cambridge, UK) was used
to measure caspase 3 activity as per manufacturer's instructions. Samples
were analysed by ﬂow cytometry as described previously in the study by
Mahbub et al.7
Nuclear morphological analysis of apoptosis using double staining of Hoechst
33342/ propidium iodide and ﬂuorescence microscopy. The effects of the
combined topoisomerase inhibitor agents/polyphenols treatments were
further investigated on the apoptotic nuclear morphological changes
using Hoechst 33342 and propidium iodide staining and ﬂuorescence
microscopy (Sigma). Cells were seeded in 12-well plates at 0.5 × 106 cells
per ml and treated for 24 h with each topoisomerase inhibitor and each
polyphenol alone and in combination at their LSD. A 0.1% (v/v) ethanol
vehicle control was also included. Following 24 h of treatments, 100 μl of
cells were transferred to a 96-well plate, 10 μl of 2 μg/ml Hoechst 33342
dye was added to each well and incubated for 5 min in the dark. This was
followed by the addition of 10 μl of 2 μg/ml propidium iodide dye and
further incubated for 15min in the dark. Plates were examined using
inverted ﬂuorescence microscope. Two hundred cells (live and apoptotic)
were counted and the percentage of apoptotic nuclei determined for each
sample. Images were captured from the ﬂuorescent microscope using
Cell-F software (Olympus).
Cell cycle analysis using propidium iodide and ﬂow cytometry
Cells were seeded in 12-well plates at 0.5 × 106 cells per ml and treated
with each topoisomerase inhibitor and polyphenols alone or in combina-
tion at their LSD for 24 h, together with a 0.1% (v/v) vehicle control.
Following treatment, cells were harvested and cell cycle progression
investigated using propidium iodide staining as described previously.8
Caspases 8 and 9 Glo luminescent assays
Cells were seeded into white 96-well plates at 2.5 × 103 cells per well and
treated with each topoisomerase inhibitor and polyphenols alone and in
combination at their LSD for 24 h, together with a 0.1% (v/v) vehicle
control. Following treatment Caspase-Glo 8 and 9 assays were used as per
manufacturer's instructions (Promega) to determine caspase 8 and 9
activity. Luminescence was measured using a Wallac Victor 2 1420 (Perkin
Elmer Coventry, UK) and was normalised to vehicle controls.
GSH-Glo glutathione assay
Basal glutathione levels were determined for the four leukaemia cell lines
(CCRF-CEM, Jurkat, KG-1a and THP-1) and the two non-tumour control cells
(CD133+ HSC and CD34+ HSC). Glutathione levels were also measured in all
cells following treatment with polyphenols and topoisomerase inhibitors
alone or in combination, for those treatments where combinations had
previously shown a synergistic or antagonistic effect.
Cells were seeded into white 96-well plates at 2.5 × 103 cells per well and
treated with each topoisomerase inhibitor and polyphenols alone and in
combination at their LSD for 24 h, together with a vehicle control.
Following treatment, glutathione levels were measured using the GSH-Glo
glutathione luminescent assay as per manufacturer's instructions.
Luminescent signal was measured using a Wallac Victor 2 1420 and
normalised to the vehicle control.
DNA damage measured by γH2AX foci detection
Alexa Fluor 647 Mouse anti-γH2AX (pS139) (BD Pharmingen, Oxford, UK) is
speciﬁcally designed for the phosphorylation of Ser-139 at the C-terminal
region of γH2AX enabling the visualisation of γH2AX by immunoﬂuores-
cence. The formation of γH2AX foci indicates the presence of DNA damage.
Cells were seeded into a BD Falcon 96-well Imaging Plate (BD Pharmingen)
at 1.0 × 103 cells per well and treated with each topoisomerase inhibitor
and polyphenols alone and in combination at their LSD for 24 h, together
with a vehicle control. Following treatments, cells were centrifuged at
400× g for 10min then washed in PBS and ﬁxed in BD Cytoﬁx ﬁxation
buffer for 10min (BD Pharmingen). The cells were then washed twice in
PBS and permeabilised in 90% methanol (Sigma) for 5 min. Following
washes, cells were incubated in 50 μl Alexa Fluor 647 Mouse anti-γH2AX
(pS139) (1 : 10 v/v) at RT for 60min in the dark. Following incubation, cells
were washed three times in PBS and counter-stained in 100 μl of 2 mg/ml
Hoechst 33342 stain for 15min. Cells were visualised using inverted
ﬂuorescence microscopy (Olympus, 1x2-UCB). Those cells with six
and more γ-H2AX foci were considered as cells with DNA damage.32
The number of cells with substantial DNA damage (⩾6 foci) or without
substantial DNA damage (o6 foci) were counted. At least 200 cells per
sample were counted and percentage of cells with substantial DNA
damage determined. Images were captured using an inverted ﬂuorescence
microscopy and the Cell-F software.
Analysis of effects of combination treatments on ATP level,
apoptosis, glutathione levels and DNA damage
The effects of the combination treatments were categorised using the
following criteria:
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● Reduction of ATP levels or induction of apoptosis or depletion of
glutathione levels or induction of γ-H2AX foci formation by a
polyphenol alone=X.
● Reduction of ATP levels or induction of apoptosis or depletion of
glutathione levels or induction of γ-H2AX foci formation by chemotherapy
agent alone=Y.
● Reduction of ATP levels or induction of apoptosis or depletion of
glutathione levels or induction of γ-H2AX foci formation by combined
polyphenol and chemotherapy agent treatment = Z.
● X+Y were calculated and described as our expected value.
The effect of combination chemotherapy and polyphenols treatments
was classiﬁed as: additive or synergistic or competitive-antagonistic or
antagonistic according to their statistical analysis using the Kruskal–Wallis
and Conover–Inman post hoc tests. The combination effects were classiﬁed
and deﬁned as follows:
1. Additive: the effect of combination treatments (Z) is equal to the sum
of the effect of the two treatments alone. This is an additive response
if the combined effect (Z) is signiﬁcantly greater than the effect
of each treatment X and Y alone, as well as, signiﬁcantly greater than
the vehicle control, but not signiﬁcantly greater than the expected
value (X+Y).
2. Synergistic: the effect of combination treatments is higher than the sum
of the effect of the two treatments alone. A synergistic response is seen
if the combined effect (Z) is signiﬁcantly greater than the vehicle
control, each treatment alone (X alone, Y alone) and the expected value
(X+Y).
3. Competitive-antagonistic: the effect of combination treatments is equal
to the effect of one of two treatments. A competitive-antagonistic
response is seen if the combined effect (Z) is signiﬁcantly lower than the
expected value (X+Y) and has a similar response to the effect of one
treatment alone (X or Y alone) and is not signiﬁcantly different.
4. Antagonistic: the effect of combination treatments is lower than the
sum of the effect of the two treatments and individual treatments alone.
An antagonistic response is seen if the combined effect (Z) is
signiﬁcantly lower than the effect of each treatment alone (X alone, Y
alone) and the expected values (X+Y).
Analysis of effect of combination treatments on cell cycle
The percentage of cells in each phase was analysed using the FlowJo
software using the Watson pragmatic model. The data were expressed as
medians with ranges (n= 4). The statistical signiﬁcance of individual drugs
was determined ﬁrst in comparison to the vehicle control using a Kruskal–
Wallis and Conover–Inman post hoc tests. The statistical signiﬁcance of
combined drugs was determined in comparison to the vehicle control and
individual treatments. The effect of combination treatments on cell cycle
was classiﬁed either as: interactive, non-interactive or antagonistic. These
classiﬁcations are deﬁned as:
1. Interactive effect: the combination treatments induce a highly
signiﬁcant increase of cell accumulation in any phase of cell cycle,
when compared with the vehicle control and those effects caused by
the individual treatment alone.
2. Non-interactive effect: the combination treatments induced a signiﬁcant
increase of cell accumulation in any phase of cell cycle when compared
with the vehicle control; but this was not signiﬁcantly greater than that
seen with one or both of treatments when used alone.
3. Antagonistic effect: the combination treatments had no signiﬁcant
difference in cell accumulation in any phase of cell cycle, when
compared with the vehicle control, and was signiﬁcant less when
compared with the phases arrested by individual treatments alone.
Statistical analysis
The median with range was calculated for the assays. Stats Direct software
(Stats Direct, Altrincham, UK) was used to test whether data followed a
normal distribution using a Shapiro–Wilke test, which was used to
determine whether the data were parametric or non-parametric. As the
data were non-parametric, a Kruskal–Wallis and Conover–Inman post hoc
tests were used to determine statistical signiﬁcance of the data. Results
were considered statistically signiﬁcant when P⩽ 0.05.
ABBREVIATIONS
DOX, doxorubicin; ETP, etoposide; QUE, quercetin; AP, apigenin; EMO,
emodin; RH, rhein; CIS, cis-stilbene.; LSD, lowest-signiﬁcant dose.
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